1, 2 CYP2D6 substrates belong to different drug classes, including antidepressants (eg, amitriptyline, doxepin, fluvoxamine, nortriptyline, fluoxetine, paroxetine), antipsychotics (eg, chlorpromazine, clozapine, haloperidol, risperidone), antiarrhythmics (eg, flecainide, propafenone), beta-blockers (eg, carvedilol, metoprolol), opioid analgesics (eg, codeine, tramadol), anticancer agents (eg, gefitinib, tamoxifen), and other drugs (eg, atomoxetine, dextromethorphan, ondansetron Pharmacogenomics Knowledge Base,, last accessed January 29, 2019). These publicly available samples will support the quality-assurance and quality-control programs of clinical laboratories performing CYP2D6 testing.ĬYP2D6 is part of the cytochrome P450 gene family, a group of phase I metabolism enzymes that are responsible for the elimination or bioactivation of numerous drugs. DNA samples were distributed to volunteer testing laboratories for genotyping using a variety of commercially available and laboratory-developed tests. Testing included the recharacterization of 137 genomic DNAs that were genotyped in previous Genetic Testing Reference Material Coordination Program studies and 42 additional samples that had not been characterized previously. To address this need, the Division of Laboratory Systems, CDC-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing and research communities and the Coriell Cell Repositories (Camden, NJ), has characterized 179 DNA samples derived from Coriell cell lines. However, only a limited number of quality control and other reference materials currently are available for the complex rearrangements and rare variants that occur in the CYP2D6 gene. Pharmacogenetic testing increasingly is available from clinical and research laboratories.
0 kommentar(er)
